Xiangyang Central Hospital ( Site 5017)

Xiangyang, Hubei 441021

1 studies enrolling now · 1 studies all time

What they study most

Triple Negative Breast Neoplasms

Studies at this site

• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) — Recruiting now